OTC · Drug Manufacturers - Specialty & Generic

DMK Pharmaceuticals Corporation (DMKPQ) Stock

$0.00 OTC: DMKPQ Healthcare

DMK Pharmaceuticals Corporation functions as a clinical-stage neuro-biotechnology company, focusing on the development and market introduction of therapeutic solutions across several medical fields, including allergies, opioid overdose, respiratory conditions, and inflammatory diseases. Its primary product candidate currently in clinical trials is DPI-125, designed for the treatment of opioid use disorder.

Valuation

MetricValue
Price$0.00
Market Cap$1010
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-12.37
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE2600.00%
ROA-236.36%
ROCE—
Gross Margin-500.00%
Operating Margin-500.00%
Net Margin-520.00%
Debt/Equity0.00
Current Ratio0.82

Annual Financials (USD)

Metric20182019202020212022
Revenue$15.0M$22.0M$3.0M$2.0M$5.0M
Operating Profit$-40.0M$-30.0M$-32.0M$-32.0M$-25.0M
Net Profit$-39.0M$-28.0M$-49.0M$-46.0M$-26.0M
EPS$-69.86$-36.16$-44.57$-22.25$-12.37
Op Margin-267.5%-135.7%-1141.0%-1452.0%-526.9%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$58.0M$48.0M$31.0M$38.0M$11.0M
Total Liabilities$12.0M$15.0M$27.0M$12.0M$12.0M
Cash$19.0M$9.0M$7.0M$23.0M$1.0M
Borrowings$3.0M$4.0M$4.0M$1.0M$0

Latest News

Low-Cost Developed Markets or Emerging-Market Tech Exposure? VEA vs. IEMG Motley Fool · Jul 23, 2026 GE Vernova’s AI power trade has one weak link TheStreet · Jul 23, 2026 Flagstar Financial Earnings: What To Look For From FLG StockStory · Jul 23, 2026 Eni and KazMunayGas Reach Key Milestone at Kazakhstan Hybrid Power Plant Oilprice.com · Jul 23, 2026 Stand-On by ABC Display Crowned Best Tradeshow Floor ACCESS Newswire · Jul 23, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-33.0M$-20.0M$-21.0M$-38.0M$-26.0M
Investing Cash Flow$-7.0M$-6.0M$-2.0M$-1.0M$3.0M
Financing Cash Flow$0$-1.0M$0$0$0
Net Cash Flow$1.0M$-10.0M$-2.0M$17.0M$-22.0M
Free Cash Flow$-36.0M$-23.0M$-22.0M$-39.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.03
FCF Yield-2631774.55%
Quick Ratio0.70
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADLIAmerican Medical Technologies Inc. $0.00 — 0.00 $1031 0.00%
AMHDHLK Biotech Holding Group, Inc. $0.00 — — $925 0.00%
BIMIBIMI International Medical Inc. $0.00 — 0.00 $1156 0.00%
CFRXQContraFect Corp. $0.00 — 0.00 $107 0.00%
EFTReFFECTOR Therapeutics, Inc. $0.00 — 0.00 $2352 0.00%

About DMK Pharmaceuticals Corporation

DMK Pharmaceuticals Corporation functions as a clinical-stage neuro-biotechnology company, focusing on the development and market introduction of therapeutic solutions across several medical fields, including allergies, opioid overdose, respiratory conditions, and inflammatory diseases. Its primary product candidate currently in clinical trials is DPI-125, designed for the treatment of opioid use disorder. The company's portfolio also encompasses SYMJEPI, an epinephrine injection used for the immediate management of severe allergic reactions (anaphylaxis) triggered by factors such as insect stings, foods, medications, or those that are idiopathic or exercise-induced. Additionally, they offer ZIMHI, a naloxone injection vital for reversing opioid overdoses. The organization, previously named Adamis Pharmaceuticals Corporation, officially rebranded to DMK Pharmaceuticals Corporation in September 2023. Headquartered in San Diego, California, DMK Pharmaceuticals Corporation, along with its associated entities, filed for voluntary Chapter 11 bankruptcy reorganization in the U.S. Bankruptcy Court for the District of Delaware on February 2, 2024.

DMK Pharmaceuticals Corporation (DMKPQ) stock trades at $0.00 with a market capitalization of $1010. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, DMK Pharmaceuticals Corporation generates a return on equity (ROE) of 2600.00% — well above the market average, a sign of a high-quality business, an operating margin of -500.00%, a net profit margin of -520.00%.

Official website: www.dmkpharmaceuticals.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides